Abstract
Introduction Pharmacogenomic (PGx) variants impact the pharmacodynamics and pharmacokinetics of opioids and the brain’s reward, cognition, stress, and pain pathways. This study examines the prevalence of PGx variants impacting opioid response among a cohort of high-risk infants.
Methods This retrospective study was conducted at a quaternary children’s hospital from 2009-2020. Infants <1y with ≥1 high-risk condition (congenital heart disease (CHD), medical or surgical necrotizing enterocolitis (NEC), thoracoabdominal surgery, very or extremely low birthweight, hypoxic ischemic encephalopathy, or extracorporeal membrane oxygenation) with exome sequencing were included. Prevalence of opioid-related variants (COMT, DRD2/ANKK1, ABCB1, OPRM1, CYP2B6, CYP2D6) were compared to Ensembl, a database of published genomic cohorts.
Results Overall, 111 high-risk infants were identified (62.2% male, 47.7% Hispanic/Latino, 18.0% premature, and 82.0% CHD). Most underwent surgery (68.2%), with 37.8% undergoing CHD surgery. Overall, 81.1% of infants were homozygous for ≥1 opioid-related variant(s). Compared to Ensembl, high-risk infants had a significantly higher frequency of homozygosity for ABCB1: rs1045642 (43.6% vs. 18.7%, p<0.001) and rs2032582 (42.7% vs. 15.9%, p<0.001). Conversely, high-risk infants had a lower frequency of homozygosity for COMT: rs4818 (2.7% vs. 10.3%, p<0.001) and OPRM1: rs1799971 (2.7% vs. 7.1%, p<0.001). All infants with surgical NEC (N=5) were homozygous for ≥1 opioid-related variant. The most common metabolizer phenotypes were intermediate (CYP2B6: 35.5%, CYP2D6: 20.0%) and normal (CYP2B6: 53.9%, CYP2D6: 70.9%).
Conclusion Most high-risk infants carried at least one opioid-related variant, with frequencies that are significantly different from broader genetic cohorts. Larger studies inclusive of intronic PGx variants using ancestrally comparable controls are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from the Children's Hospital Los Angeles Review Board (CHLA-23-00335).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
No funding to disclose
Data Availability
All data produced in the present work are contained in the manuscript.
